Intraoperative Mechanical Ventilation and Postoperative Pulmonary Complications After On-pump Cardiac Surgery in High-risk Patients (VACARM)

May 19, 2023 updated by: Rennes University Hospital

Effect of IntraoperatiVe High Positive End-ExpirAtory Pressure (PEEP) With ReCruitment MAneuveRs vs Low PEEP on Major Postoperative Pulmonary Complications and Death After On-pump Cardiac Surgery in High-risk Patients: the VACARM Study

Controversies remain concerning the best intraoperative mechanical ventilation regimen for major cardiac surgery. While the use of intra operative low tidal volumes is now standard practice, the optimal level of positive end-expiratory pressure (PEEP) and the use of recruitment maneuvers (RM) remain controversial. The aim of this study is to compare two regimens of intraoperative mechanical ventilation on postoperative outcomes in cardiac surgery patients at risk of postoperative pulmonary complications

Study Overview

Detailed Description

In this randomized controlled trial, cardiac surgery patients at risk of postoperative pulmonary complications will be assigned to intraoperative ventilation with high PEEP and RM or intraoperative mechanical ventilation with low PEEP and without RM. The primary endpoint will be a composite endpoint including major postoperative complications within the first postoperative week and death within the 28 days after surgery

Study Type

Interventional

Enrollment (Anticipated)

440

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Amiens, France
        • Not yet recruiting
        • CHU Amiens-Picardie
        • Contact:
          • Osama ABOU ARAB, Dr
      • Angers, France
        • Withdrawn
        • Chu Angers
      • Brest, France
        • Recruiting
        • CHRU Brest
        • Contact:
          • Jean-Ferréol OILLEAU, Dr
      • Poitiers, France
        • Not yet recruiting
        • CHU Poitiers
        • Contact:
          • Thomas KERFONE, Dr
      • Rennes, France
        • Recruiting
        • CHU Rennes
        • Contact:
          • Nathalie DEMAURE
        • Principal Investigator:
          • Nicolas NESSELER, Dr
        • Principal Investigator:
          • Nathalie DEMAURE
      • Saint-Herblain, France
        • Recruiting
        • CHU Nantes
        • Contact:
          • Bertrand ROZEC, Pr
      • Tours, France
        • Recruiting
        • CHRU Tours
        • Contact:
          • Fabien ESPITALIER, Dr

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients older than 18 years-old,
  • Evaluated before cardiopulmonary bypass for any cardiac surgical procedure (e.g. coronary artery bypass grafting, valve, aorta, or combined procedures),
  • With a pulmonary risk score ≥ 2
  • Who gave written informed consent
  • affiliated to a social security system

Exclusion Criteria:

  • BMI > 40kg/m2 ;
  • Left Ventricular Ejection Fraction < 35% ;
  • Preoperative shock ;
  • Aortic surgery with planned circulatory arrest ;
  • Minimally invasive cardiac surgery ;
  • Emergency surgery with patient unable to give written informed consent
  • Heart transplantation
  • Mechanical circulatory support surgery
  • Pregnant or lactating women
  • Adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group_MRA
Recruitment maneuvers and high PEEP

Tidal Volume (Vt) =6-8 mL/kg of predicted body weight (PBW), Peep=8 cmH2O, recruitment maneuvers=30cm H2O every 30 min after intubation (except during CPB), after any disconnection and at the admission in ICU.

Recruitment maneuvers are performed in accordance with the surgical team an if SAP≥90 mmHg or MAP≥65 mmHg.

Ventilation is maintained during CPB Vt=2.5 mL/kg, Peep= 5 cmH2O

Other Names:
  • recruitment maneuvers
Active Comparator: Control group
No recruitment maneuvers and low PEEP
Vt=6-8 mL/kg of PBW, Peep=5 cmH2O , No recruitment maneuvers. Ventilation maintained during CPB Vt=2.5 mL/kg, Peep= 5 cmH2O.
Other Names:
  • NO recruitment maneuvers

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of major pulmonary complications and death
Time Frame: 28 days after surgery
Major pulmonary complications, defined as prolonged mechanical ventilation >24h post-operatively, pneumonia (defined according to the 2017 French guidelines) or reintubation for any cause within 7 post-operative days, or death
28 days after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mortality rate
Time Frame: Day 28
Day 28
Rate of patients with hypotension
Time Frame: intraoperative period
Hypotension lasting more than 60 seconds after the end of the recruitment maneuvers
intraoperative period
Evaluate the postoperative blood gases
Time Frame: 30 minutes after extubation
Measure of PaO2 (mmHg)
30 minutes after extubation
Evaluate the postoperative blood gases
Time Frame: 30 minutes after extubation
Measure of HCO3 (mmol/l)
30 minutes after extubation
Evaluate the postoperative blood gases
Time Frame: 30 minutes after extubation
Measure of PaCO2 (mmHg)
30 minutes after extubation
Evaluate the postoperative blood gases
Time Frame: 30 minutes after extubation
Measure of SaO2 (%)
30 minutes after extubation
Evaluate the postoperative blood gases
Time Frame: Day 1
Measure of PaO2 (mmHg)
Day 1
Evaluate the postoperative blood gases
Time Frame: Day 1
Measure of HCO3 (mmol/l)
Day 1
Evaluate the postoperative blood gases
Time Frame: Day 1
Measure of PaCO2 (mmHg)
Day 1
Evaluate the postoperative blood gases
Time Frame: Day 1
Measure of SaO2 (%)
Day 1
Evaluate the postoperative blood gases
Time Frame: Day 2
Measure of PaO2 (mmHg)
Day 2
Evaluate the postoperative blood gases
Time Frame: Day 2
Measure of HCO3 (mmol/l)
Day 2
Evaluate the postoperative blood gases
Time Frame: Day 2
Measure of PaCO2 (mmHg)
Day 2
Evaluate the postoperative blood gases
Time Frame: Day 2
Measure of SaO2 (%)
Day 2
Pulmonary function tests
Time Frame: Day 0
Measure of vital capacity (CV) and maximum expiratory volume by second (VEMS) by spirometry
Day 0
Pulmonary function tests
Time Frame: Day 3
Measure of vital capacity (CV) and maximum expiratory volume by second (VEMS) by spirometry
Day 3
Pulmonary function tests
Time Frame: Day 5
Measure of vital capacity (CV) and maximum expiratory volume by second (VEMS) by spirometry
Day 5
Daily evaluation of organ failure
Time Frame: Up to 7 days
SOFA score
Up to 7 days
Daily evaluation of delirium
Time Frame: Up to 7 days
CAM-ICU scale
Up to 7 days
Rate of Postoperative pulmonary complications (PPC)
Time Frame: within the 28 days after surgery
Pneumonia (defined according to the 2017 French guidelines), re-intubation within 7 days, mechanical ventilation >24h, pneumothorax, Atelectasis, Acute Respiratory Distress Syndrome. PPC grade (according to Huzelbos et al; JAMA)
within the 28 days after surgery
Rate of Postoperative non pulmonary complications
Time Frame: within the 28 days after surgery
Re intervention for acute bleeding, Pericardial Tamponade, Sternal wound infection, Ventricular Arrhythmia, Atrial fibrillation, Myocardial infarction, Mesenteric ischemia, Sepsis/septic shock, Acute kidney injury with renal replacement
within the 28 days after surgery
Ventilation duration, length of stay in ICU and in the study hospital and death
Time Frame: Day 28
Number of Ventilatory-free days, vasopressor-free days, ICU-free days and hospital-free days
Day 28
Mortality rate
Time Frame: Day 90
Day 90
Mortality rate
Time Frame: Day 180
Day 180
Biomarkers of systemic inflammation and of epithelial and endothelial aggression
Time Frame: Day 0
Plasma levels of TNFα, IL1β, IL6, IL8 et IL10, Angiopoeitin 2 and soluble form of receptor for advanced glycation end products (sRAGE)
Day 0
Biomarkers of systemic inflammation and of epithelial and endothelial aggression
Time Frame: Day 1
Plasma levels of TNFα, IL1β, IL6, IL8 et IL10, Angiopoeitin 2 and soluble form of receptor for advanced glycation end products (sRAGE)
Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Nathalie DEMAURE, CHU Rennes
  • Principal Investigator: Nicolas NESSELER, Dr, CHU Rennes
  • Principal Investigator: Jean-Ferréol OILLEAU, Dr, CHRU Brest
  • Principal Investigator: Emmanuelle LONGEAU, Dr, University Hospital, Angers
  • Principal Investigator: Bertrand ROZEC, Pr, CHU Nantes
  • Principal Investigator: Thomas KERFONE, Dr, CHU Poitiers
  • Principal Investigator: Fabien ESPITALIER, Dr, CHRU Tours
  • Principal Investigator: Osama ABOU ARAB, Dr, CHU Amiens-Picardie

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 8, 2021

Primary Completion (Anticipated)

August 8, 2025

Study Completion (Anticipated)

July 8, 2026

Study Registration Dates

First Submitted

May 15, 2020

First Submitted That Met QC Criteria

May 25, 2020

First Posted (Actual)

May 29, 2020

Study Record Updates

Last Update Posted (Actual)

May 22, 2023

Last Update Submitted That Met QC Criteria

May 19, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postoperative Pulmonary Complications

Clinical Trials on Intervention group_MRA

3
Subscribe